Cool . . . but could you send me the guy's number by PM, please.

"As of the end of September 2008, more than 35,500 patients were on commercial and clinical TYSABRI therapy worldwide. According to data available as of the end of September 2008:

* In the U.S., more than 19,500 patients were on TYSABRI therapy commercially;
* Outside of the U.S., nearly 15,300 patients were on TYSABRI therapy commercially;
* In global clinical trials, more than 700 patients were on TYSABRI therapy; and
* There have been two confirmed cases of progressive multifocal leukoencephalopathy (PML) since re-launch in the US and the first international approval in July 2006.

(NOTE: That adds up to 35,500 . . . which is how many are ON Tysabri).

Cumulatively, in the combined clinical trial and post-marketing settings:

* More than 48,000 patients have been treated with TYSABRI; and
* Of those patients, nearly 18,000 have received at least one year of TYSABRI therapy and approximately 9,500 patients have been on therapy for 18 months or longer."

http://findarticles.com/p/articles/m..._/ai_n30915367

http://seekingalpha.com/article/1008...nscript?page=3

Cherie